Beruflich Dokumente
Kultur Dokumente
Timothy W. Fong MD UCLA Addiction Medicine Clinic UCLA Addiction Psychiatry Fellowship DSM-5 What You Need to Know June 8, 2013
Financial Disclosures
Speaker Bureau Reckitt Benckiser Pfizer one80 Research Support NIDA OPG (California) Annenberg Foundation AACI Psyadon
Overview
DSM-IV Toward DSM-5 DSM-5 Clinical Implications
DSM-IV (1994)
27 member Task Force 13 Work Groups
50-100 advisors, over 1000 participants
Published in five volume Sourcebook Comprehensive literature reviews Field trials Inclusion of Clinical Significance Criterion
DSM-IV TR (2000)
Changes made in the descriptive text Changes made to a handful of criteria sets Some diagnostic codes were changed to reflect updates to the ICD-9 coding system Available in 22 languages
Substance-Induced Disorders
Persisting Dementia Persisting Amnestic Disorder Psychotic Disorder with Delusions/ Hallucinations Mood Disorder Anxiety Disorder Sleep Disorder
DSM-V Workgroup
DSM V Workgroup on Substance-Related Disorders was convened in 2007 in order to better describe the current category of Substance Use Disorders Explored whether the diagnoses encompassing Substance-Related Disorders in DSM-IV reflect current and clinically useful understanding of this disease.
DSM-V
Workgroup
Marc Auriacombe, M.D. Alan J. Budney, Ph.D. Wilson M. Compton, M.D. Thomas J. Crowley, M.D. Bridget F. Grant, Ph.D., Ph.D. Deborah S. Hasin, Ph.D. Walter Ling, M.D. Charles P. OBrien, M.D. Nancy Petry, Ph.D.
18
Preliminary Workgroup Recommendations: Chapter Heading Addictions and Related Disorders Substance, Gambling and Related Disorders Appetitive Behavior and Related Disorders
19
Withdrawal
Occurs with decline in blood/tissue levels
Dimensional Ratings
Provide richer characterization of patients condition
Document all symptoms
Severity
No disorder (0) mild (1-3) moderate (4-5), severe (6+)
Specifiers
Early remission
3-12 months
Sustained remission
>12 months
New specifiers
in a controlled environment on maintenance therapy
Cannabis Withdrawal
Irritability/Anger/Aggression Anxiety/nervousness Insomnia Decreased Appetite / Weight Loss Restlessness Depressed mood Physical C/O (non-specific)
Caffeine Withdrawal
Formerly, in DSM-IV Appendix
Headache. Marked fatigue or drowsiness. Dysphoric mood, depressed mood, or irritability. Difficulty concentrating. Flu-like symptoms (nausea, vomiting, or muscle pain/stiffness
DSM-V Improvements
Helps to differentiate compulsive behavior (addiction) vs. normal responses to drug-taking behavior (dependence) No more diagnostic orphans Substance-Induced Mental D/O moved to respective primary d/o sections
Clinical Implications
Clinical Implications
Handling milder symptoms
Reimbursement issues
Dealing with change in severity over time Missing out on false negatives ?
(+ abuse but for SUD)
Recording Procedures
Use specific name of substance Severity modifier first
Moderate alcohol use disorder
Consequences
Epidemiology: Epidemic or Rare Disease Research Core of what we study Treatment What are we treating? Policy Disease, excessive behavior Societal View Stigma
Contact Information Timothy Fong MD UCLA Addiction Medicine Clinic 310-825-9989 (appts) 310-825-1479 (office) tfong@mednet.ucla.edu uclagamblingprogram.org